NCT04967287View on ClinicalTrials.gov

MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation

NACompletedINTERVENTIONAL

Enrollment

124

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

October 4, 2024

Study Completion Date

October 4, 2024

Conditions

Myopia

Interventions

DEVICE

MyopiaX

MyopiaX treatment twice a day

DEVICE

Myopia control spectacles

To be used all as prescribed

Trial Locations (10)

40549

MVZ Makula-Netzhaut-Zentrum Breyer Kaymak Klabe, Düsseldorf

Unknown

Suedblick GmbH, Augsburg

BeyondEye Clinic, Cologne

University Medical Center, Johannes Gutenberg- University, Mainz

University Eye Hospital Tübingen, Tübingen

Erasmus University Medical Center, Rotterdam

University of Minho, Braga

Hospital Sant Joan de Déu, Barcelona

University Complutense of Madrid, Madrid

Moorfields Eye Hospital NHS Fundation Trust, London

All Listed Sponsors

lead

Dopavision GmbH

INDUSTRY

NCT04967287 - MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation | Biotech Hunter | Biotech Hunter